Showing results (371-380 of 413) with videos related to
Sort By:
Pageof 42
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceG Berclaz, S Li, K N Price, et al.Plos One|July 15, 2011
Transcriptome sequencing, and rapid development and application of SNP markers for the legume pod borer Maruca vitrata (Lepidoptera: Crambidae)Venu M Margam, Brad S Coates, Darrell O Bayles, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VIID Crivellari, M Bonetti, M Castiglione-Gertsch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.Insect Molecular Biology|November 15, 2015
Quantitative trait locus mapping and functional genomics of an organophosphate resistance trait in the western corn rootworm, Diabrotica virgifera virgiferaB S Coates, A P Alves, H Wang, et al.Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.Cancer|March 26, 2003
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial VVito J Spataro, Heather Litman, Giuseppe Viale, et al.The Lancet. Oncology|December 18, 2007
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialBirgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, et al.Pageof 42